ClinicalTrials.gg
RecruitingNCT07287423Updated Oct 16, 2026

LEAP 2 Chronic EFS

An interventional study of AVEIR CSP Leadless Pacemaker System in Cardiac Pacemaker, Cardiac Rhythm Disorder and Bradycardia, sponsored by Abbott Medical Devices. Recruiting at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Primary conditionBradycardiaRegistry: Arrhythmias, CardiacReclassifiedWhy we changed it
Registry
Arrhythmias, Cardiac — the first condition term the registry derived for this study.
ClinicalTrials.gg
Bradycardia
Why
  1. The study's listed conditions name Bradycardia, a narrower term within Arrhythmias, Cardiac.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Abbott Medical Devices (part of Abbott) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 16, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Bradycardia by Abbott — 5 open to participants now, 8 under way, none of them phase 3. Bradycardia · Abbott.

Planned enrollment
11th of 11
30 · median 249
Started
2025
with 1 other
No phase
10 of 28
2 open now
Registered
27th of 28
by date

Among the 28 studies in Bradycardia by Abbott, this one is the 11th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2025, is one of 10 with no phase, and was the 27th registered.

Bradycardia

317 studies on the registry are indexed under Bradycardia; 71 are open to participants now.

Browse Bradycardia studies →

Open to participants now

5 of the 28 studies in Bradycardia by Abbott are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 51 Bradycardia studies recruiting now, 34 (67%) set no upper age limit and 9 (18%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Bradycardia by Abbott, or all of them as a file.
02

Study summary

Prospective, single-arm, non-randomized, unblinded, chronic feasibility study designed to evaluate the safety and performance of the AVEIR™ Conduction System Pacing (CSP) Leadless Pacemaker system.

Read the detailed description

The purpose of this clinical investigation is to evaluate the chronic safety and performance of the AVEIR CSP Leadless Pacemaker system in a patient population with standard pacing indications.

Subjects participating in the study will have data collected at baseline, implant procedure, pre (hospital) discharge, and follow-up at 1 month, 2 months, 3 months, 6 months, 12 months, and every 6 months thereafter until study completion

03

Conditions studied

  • Cardiac Pacemaker
  • Cardiac Rhythm Disorder
  • Bradycardia

Browse trials for

Keywords

  • Bradycardia
  • Sick Sinus Syndrome
  • Pacemaker
  • Leadless
  • Conduction System Pacing
  • LBBAP
04

In context

Bradycardia Reclassified

317 studies on the registry are indexed under Bradycardia; 71 are open to participants now.

This study's planned enrollment of 30 is below the median of 100 across 187 interventional studies indexed under Bradycardia.

Browse Bradycardia studies →

Lead sponsor

Abbott Medical Devices is the lead sponsor of 541 studies on the registry; 34 are open to participants now.

Of its 53 completed or terminated interventional studies of FDA-regulated products, 44 (83%) have results posted.

Compared within Bradycardia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Arrhythmias, Cardiac. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must have at least one standard pacemaker indication
  2. Subject must be at least 18 years of age
  3. Subject is willing to comply with clinical investigation procedures and agrees to return to clinic for all required follow-up visits, tests, and exams
  4. Subject has been informed of the nature of the clinical investigation, agrees to its provisions and has provided a signed written , as approved by the local EC

Exclusion criteria

Exclusion Criteria:

  1. Subject has a mechanical tricuspid valve, percutaneous tricuspid valve repair or replacement, or an implanted vena cava filter
  2. Subject has evidence of tricuspid stenosis, tricuspid atresia, or presence of any condition that precludes appropriate vascular access for the study procedure
  3. Subject has previous myocardial infarction
  4. Subject is expected to be pacemaker dependent
  5. Subject has a previous or existing lead or device in the right heart or interventricular septum (includes lead fragments, temporary pacing leads, and closure devices)
  6. Subject has an active implantable electronic device that cannot be turned off during the study procedure
  7. Subject has recent cardiovascular or peripheral vascular surgery within 30 days of enrollment
  8. Subject has known allergy or to \< 1 mg of dexamethasone sodium phosphate or any blood or tissue contacting material used in the study procedure
  9. Subject is unable to receive heparin or an acceptable alternative to achieve adequate anticoagulation
  10. Subject has known chronic renal insufficiency including patients on dialysis
  11. Subject has an active systemic infection
  12. Subject has known history or repair of an atrial septal defect, patent foramen ovale, or ventricular septal defect
  13. Subject is currently participating in another clinical investigation that might impact the outcomes of the clinical investigation
  14. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period
  15. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with the follow-up requirements of the clinical investigation
  16. Subject is unable to read or write
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Treatment Arm

    Device: AVEIR CSP Leadless Pacemaker System

Interventions

  • DeviceAVEIR CSP Leadless Pacemaker System

    Patients will undergo a single or dual-chamber leadless pacemaker system implant wherein an investigational AVEIR CSP leadless pacemaker will be implanted in the right ventricle. Then, a commercial AVEIR AR leadless pacemaker may optionally be co-implanted in the right atrium, if indicated.

07

What researchers measure

Primary outcomes

  1. Percentage of Participants Free From AVEIR CSP related Complications at 1-month

    AVEIR CSP Leadless Pacemaker (LP) System complication-free-rate. A complication is defined as an AVEIR CSP LP device or AVEIR CSP procedure-related serious adverse event.

    Time frame: 1 month

  2. Average AVEIR CSP LP Pacing Thresholds and Sense Amplitude Measurements at 1-month

    Pacing Thresholds at 0.4 ms pulse width and sense amplitudes of the AVEIR CSP LP by capture type at 1 month.

    Time frame: 1 month

Secondary outcomes

  1. Percentage of Participants Free From AVEIR CSP related Complications at 3-months

    AVEIR CSP Leadless Pacemaker (LP) System complication-free-rate. A complication is defined as an AVEIR CSP LP device or AVEIR CSP procedure-related serious adverse event.

    Time frame: 3 months

  2. Average AVEIR CSP LP Pacing Thresholds and Sense Amplitude Measurements at 3 months

    Pacing Thresholds at 0.4 ms pulse width and sense amplitudes of the AVEIR CSP LP by capture type at 3 months.

    Time frame: 3 months

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes — Any de-identified individual participant data collected will be shared with investigators or other study committee members whose proposed use of the data has been approved by the Study Principal Investigator

Supporting information: Study protocol

Time frame: IPD will be available following publication of primary results for 25 years following study completion date.

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jul 2027, 19 months after the start.

Of 36 industry-sponsored interventional studies with no phase under Bradycardia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's planned 19 months is close to that.

Counting every sponsor, half of 83 studies reached it within 21 months; a quarter within 12 and three quarters within 38.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jul 2027, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2025
First posted
Dec 17, 2025
StartActual
Dec 13, 2025
Primary completionEst.
Jul 2027was Sep 2026
CompletionEst.
Dec 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Jul 2027
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Primary completion Sep 2026→Jul 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07287423
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Dec 13, 2025
Primary completion
Jul 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Kwangdeok Lee, PhD
Contact
kwangdeok.lee@abbott.com
972-526-9673
Vivek Y Reddy, MD
principal investigator · The Mount Sinai Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion